Bristol Myers Squibb Stock Current Liabilities
BMY Stock | USD 48.86 0.13 0.27% |
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.
At this time, Bristol Myers' Total Current Liabilities is fairly stable compared to the past year. Non Current Liabilities Total is likely to rise to about 45.6 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 376.2 M in 2024. Bristol | Current Liabilities |
Bristol Myers Squibb Company Current Liabilities Analysis
Bristol Myers' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Bristol Myers Current Liabilities | 8.02 B |
Most of Bristol Myers' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bristol Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Bristol Myers is extremely important. It helps to project a fair market value of Bristol Stock properly, considering its historical fundamentals such as Current Liabilities. Since Bristol Myers' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bristol Myers' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bristol Myers' interrelated accounts and indicators.
Click cells to compare fundamentals
Bristol Current Liabilities Historical Pattern
Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bristol Myers current liabilities as a starting point in their analysis.
Bristol Myers Current Liabilities |
Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
Bristol Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Bristol Myers Squibb has a Current Liabilities of 8.02 B. This is 357.52% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current liabilities for all United States stocks is 1.45% lower than that of the firm.
Bristol Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in current liabilities category among related companies.
Bristol Myers ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Bristol Fundamentals
Return On Equity | 0.27 | ||||
Return On Asset | 0.0563 | ||||
Profit Margin | 0.18 % | ||||
Operating Margin | 0.17 % | ||||
Current Valuation | 128.67 B | ||||
Shares Outstanding | 2.03 B | ||||
Shares Owned By Insiders | 0.10 % | ||||
Shares Owned By Institutions | 79.02 % | ||||
Number Of Shares Shorted | 35.12 M | ||||
Price To Earning | 24.88 X | ||||
Price To Book | 3.32 X | ||||
Price To Sales | 2.17 X | ||||
Revenue | 45.01 B | ||||
Gross Profit | 36.38 B | ||||
EBITDA | 19.18 B | ||||
Net Income | 8.04 B | ||||
Cash And Equivalents | 9.12 B | ||||
Cash Per Share | 6.21 X | ||||
Total Debt | 41.46 B | ||||
Debt To Equity | 1.32 % | ||||
Current Ratio | 1.42 X | ||||
Book Value Per Share | 14.56 X | ||||
Cash Flow From Operations | 13.86 B | ||||
Short Ratio | 1.77 X | ||||
Earnings Per Share | 3.86 X | ||||
Price To Earnings To Growth | 2.24 X | ||||
Target Price | 52.41 | ||||
Number Of Employees | 34.1 K | ||||
Beta | 0.39 | ||||
Market Capitalization | 99.29 B | ||||
Total Asset | 95.16 B | ||||
Retained Earnings | 28.77 B | ||||
Working Capital | 9.51 B | ||||
Current Asset | 10.41 B | ||||
Current Liabilities | 8.02 B | ||||
Annual Yield | 0.05 % | ||||
Five Year Return | 2.96 % | ||||
Net Asset | 95.16 B | ||||
Last Dividend Paid | 2.31 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
0.62 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
Moving against Bristol Stock
0.48 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bristol Myers Piotroski F Score and Bristol Myers Altman Z Score analysis. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.